Open Access

Antibody response against cancer‑testis antigens MAGEA4 and MAGEA10 in patients with melanoma

  • Authors:
    • Kadri Õunap
    • Kristiina Kurg
    • Liisi Võsa
    • Ülo Maiväli
    • Marina Teras
    • Anu Planken
    • Mart Ustav
    • Reet Kurg
  • View Affiliations

  • Published online on: May 10, 2018     https://doi.org/10.3892/ol.2018.8684
  • Pages: 211-218
  • Copyright: © Õunap et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Melanoma‑associated antigen A (MAGEA) represent a class of tumor antigens that are expressed in a variety of malignant tumors, however, their expression in healthy normal tissues is restricted to germ cells of testis, fetal ovary and placenta. The restricted expression and immunogenicity of these antigens make them ideal targets for immunotherapy in human cancer. In the present study the presence of naturally occurring antibodies against two MAGEA subfamily proteins, MAGEA4 and MAGEA10, was analyzed in patients with melanoma at different stages of disease. Results indicated that the anti‑MAGEA4/MAGEA10 immune response in melanoma patients was heterogeneous, with only ~8% of patients having a strong response. Comparing the number of strongly responding patients between different stages of disease revealed that the highest number of strong responses was detected among stage II melanoma patients. These findings support the model that the immune system is involved in the control of melanoma in the early stages of disease.
View Figures
View References

Related Articles

Journal Cover

July-2018
Volume 16 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Õunap K, Kurg K, Võsa L, Maiväli Ü, Teras M, Planken A, Ustav M and Kurg R: Antibody response against cancer‑testis antigens MAGEA4 and MAGEA10 in patients with melanoma. Oncol Lett 16: 211-218, 2018
APA
Õunap, K., Kurg, K., Võsa, L., Maiväli, Ü., Teras, M., Planken, A. ... Kurg, R. (2018). Antibody response against cancer‑testis antigens MAGEA4 and MAGEA10 in patients with melanoma. Oncology Letters, 16, 211-218. https://doi.org/10.3892/ol.2018.8684
MLA
Õunap, K., Kurg, K., Võsa, L., Maiväli, Ü., Teras, M., Planken, A., Ustav, M., Kurg, R."Antibody response against cancer‑testis antigens MAGEA4 and MAGEA10 in patients with melanoma". Oncology Letters 16.1 (2018): 211-218.
Chicago
Õunap, K., Kurg, K., Võsa, L., Maiväli, Ü., Teras, M., Planken, A., Ustav, M., Kurg, R."Antibody response against cancer‑testis antigens MAGEA4 and MAGEA10 in patients with melanoma". Oncology Letters 16, no. 1 (2018): 211-218. https://doi.org/10.3892/ol.2018.8684